Literature DB >> 21086135

Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells.

Osamu Yamada1, Kohji Ozaki, Mayuka Nakatake, Yasutaka Kakiuchi, Masaharu Akiyama, Tsuyoshi Mitsuishi, Kiyotaka Kawauchi, Rumiko Matsuoka.   

Abstract

We have shown previously that PI3K/Akt pathway is active after cell differentiation in HL60 cells. In the present study, we have investigated whether additional molecules, such as protein kinase C (PKC), are involved in the regulation, not only of telomerase, but also of leukemia cell differentiation. We show that PKC activates telomerase and is, itself, activated following VD3- or ATRA-induced differentiation of HL60 cells, as was observed for PI3K/Akt. To clarify the significance of PI3K/Akt and PKC pathway activation in leukemia cell differentiation, we examined the active proteins in either the downstream or upstream regulation of these pathways. In conjunction with the activation of Akt or PKC, mTOR and S6K were phosphorylated and the protein expression levels of Rictor were increased, compared with Raptor, following cell differentiation. Silencing by Rictor siRNA resulted in the attenuation of Akt phosphorylation on Ser473 and PKCα/βII phosphorylation, as well as the inhibition of Rictor itself, suggesting that Rictor is an upstream regulator of both Akt and PKC. In addition, in cells induced to differentiate by ATRA or VD3, Nitroblue-tetrazolium (NBT) reduction and esterase activity, were blocked either by LY294002, a PI3K inhibitor, or by BIM, a PKC inhibitor, without affecting cell surface markers such as CD11b or CD14. Intriguingly, the silencing of Rictor by its siRNA also suppressed the reducing ability of NBT following VD3-induced cell differentiation. Taken together, our results show that Rictor associated with mTOR (mTORC2) regulates the activity of both Akt and PKC that are involved in cell functions such as NBT reduction and esterase activity induced by leukemia cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21086135     DOI: 10.1007/s00418-010-0764-0

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  29 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Effects of 1,25-dihydroxy vitamin D3 on all-trans retinoic acid sensitive and resistant acute promyelocytic leukemia cells.

Authors:  M Giannì; M Terao; C Gambacorti-Passerini; A Rambaldi; E Garattini
Journal:  Biochem Biophys Res Commun       Date:  1996-07-05       Impact factor: 3.575

4.  AKT pathway is activated by 1, 25-dihydroxyvitamin D3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells.

Authors:  Yingyu Zhang; Jing Zhang; George P Studzinski
Journal:  Cell Cycle       Date:  2006-02-15       Impact factor: 4.534

5.  Esterases in human leukocytes.

Authors:  C Y Li; K W Lam; L T Yam
Journal:  J Histochem Cytochem       Date:  1973-01       Impact factor: 2.479

6.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.

Authors:  Marina K Holz; Bryan A Ballif; Steven P Gygi; John Blenis
Journal:  Cell       Date:  2005-11-18       Impact factor: 41.582

7.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

Review 8.  Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.

Authors:  C A Sparks; D A Guertin
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

9.  Down-regulation of telomerase activity is an early event of cellular differentiation without apparent telomeric DNA change.

Authors:  O Yamada; M Takanashi; M Ujihara; H Mizoguchi
Journal:  Leuk Res       Date:  1998-08       Impact factor: 3.156

Review 10.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

View more
  5 in total

Review 1.  Histochemistry and cell biology: the annual review 2010.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2011-01-29       Impact factor: 4.304

2.  Enzastaurin enhances ATRA-induced differentiation of acute myeloid leukemia cells.

Authors:  Ze-Yi Li; Cui Liang; Ming Ding; Xiang-Qin Weng; Yan Sheng; Jing Wu; Hao Lu; Xun Cai
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

3.  Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.

Authors:  Sadhna Dhingra; Michelle E Rodriguez; Qi Shen; Xuizhen Duan; Melissa L Stanton; Lei Chen; Rongzhen Zhang; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-01-28

Review 4.  mTOR signaling for biological control and cancer.

Authors:  Anya Alayev; Marina K Holz
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

5.  All-trans retinoic acid and protein kinase C α/β1 inhibitor combined treatment targets cancer stem cells and impairs breast tumor progression.

Authors:  Damian Emilio Berardi; Lizeth Ariza Bareño; Natalia Amigo; Luciana Cañonero; Maria de Las Nieves Pelagatti; Andrea Nora Motter; María Agustina Taruselli; María Inés Díaz Bessone; Stefano Martin Cirigliano; Alexis Edelstein; María Giselle Peters; Miriam Diament; Alejandro Jorge Urtreger; Laura Beatriz Todaro
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.